On Monday, U.S. heart valve manufacturer Edwards Lifesciences Corporation (NYSE:EW) faced an EU antitrust complaint from Indian competitor Meril, alleging anti-competitive behavior, particularly concerning patents.  This could potentially intensify EU regulators’ scrutiny of Edwards, Reuters reports.  Recent regulatory actions in the United States and Europe aim to promote fair competition and maintain drug and product affordability, especially for smaller innovative companies challenging larger incumbents. Meril has formally complained to the European Commission, citing longstanding disputes over heart valve patents spanning various global jurisdictions.  Renowned for its ...